Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218629

SCHEMBL23218629

SCHEMBL23218629

CCCc1oc2ccc(Br)cc2c1COc1cc(C)ccc1CC(=O)OCC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ TSHR P16473 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ MAPT P10636 9/20 0.36
▸ ALOX5 P09917 3/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ TP53 P04637 2/20 0.34
▸ MAPK1 P28482 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MCOLN3 Q8TDD5 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852477 1.00 HSD11B1 (0.37) HSD11B1CA12CA9TSHRLMNA
SCHEMBL29591940 0.93 CA12 (0.38) CA12CA9TSHRLMNAMAPT
SCHEMBL29852819 0.93 CA12 (0.38) CA12CA9TSHRLMNAMAPT
SCHEMBL23218701 0.93 CA12 (0.38) CA12CA9TSHRLMNAMAPT
SCHEMBL29852502 0.90 TSHR (0.40) TSHRMAPTTP53KDM4EALDH1A1
SCHEMBL23218934 0.90 TSHR (0.40) TSHRMAPTTP53KDM4EALDH1A1
SCHEMBL29592393 0.90 TSHR (0.40) TSHRMAPTTP53KDM4EALDH1A1
SCHEMBL23218653 0.90 TBXAS1 (0.39) CA12CA9TSHRLMNAMAPT
SCHEMBL29853101 0.90 TBXAS1 (0.39) CA12CA9TSHRLMNAMAPT
SCHEMBL23218063 0.89 CA12 (0.39) CA12CA9TSHRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB HSD11B1 573/4885CA12 1610/4885CA9 862/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB HSD11B1 1336/4885CA12 4035/4885CA9 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.